Vivek Subbiah: The power of Tissue-Agnostic in Precision Medicine

Vivek Subbiah shared a post by Antonio Calles, Head, Lung Cancer Unit at Hospital Ruber Internacional, on X, adding:

“Great case to show the power of Tissue-Agnostic Precision Medicine.

That’s why we need tissue-agnostic drug approvals so patients with rare diseases can have access to these therapies.”

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

Authors: Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein, Patrick Y. Wen, Sascha Dietrich, Maja J. A. de Jonge, Jean-Yves Blay, Antoine Italiano, Kan Yonemori, Daniel C. Cho, Filip Y. F. L. de Vos, Philippe Moreau, Elena Elez Fernandez, Jan H. M. Schellens, Christoph C. Zielinski, Suman Redhu, Aislyn Boran, Vanessa Q. Passos, Palanichamy Ilankumaran and  Yung-Jue Bang.

Quoting Antonio Calles: 

“Even in ultra-rare tumors like this relapsed BRAF V600E-mutant metastasic malignant glomus tumor, tumor agnostic treatment with BRAF + MEK inhibitors encorafenib plus binimetinib led to complete response and long lasting benefit. Check out this case.”

Complete response to encorafenib plus binimetinib in a BRAF V600E-mutant metastasic malignant glomus tumor

Authors: Marta Arregui, Antonio Calles, María Del Mar Galera, Ana Gutiérrez, Carlos López-Jiménez, Carolina Agra, Adriana Fernández, Natalia Gutiérrez, María de Toro and Rosa Álvarez.

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.